JNJ trades at $270, inches from its $276 52-week high, with raised guidance and FDA robotic approval already priced into **** yst consensus.
JNJ's 32% YTD gain nearly triples SPY's 12% return, yet a trailing P/E of 31 leaves little margin for earnings disappointment.
Tremfya surged 71% and Darzalex topped $4 billion in Q2, but Stelara's 56% decline continues to pressure free cash flow toward a $21 billion target.
Act now: the **** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.
At $270.24, Johnson & Johnson (NYSE:JNJ) is a hold. The stock has run to within striking distance of its 52-week high of $276.47 after a raised guide and robotics approval, and the setup at this price deserves careful consideration rather than a reflexive chase.
#raised #analyst
JNJ's 32% YTD gain nearly triples SPY's 12% return, yet a trailing P/E of 31 leaves little margin for earnings disappointment.
Tremfya surged 71% and Darzalex topped $4 billion in Q2, but Stelara's 56% decline continues to pressure free cash flow toward a $21 billion target.
Act now: the **** yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.
At $270.24, Johnson & Johnson (NYSE:JNJ) is a hold. The stock has run to within striking distance of its 52-week high of $276.47 after a raised guide and robotics approval, and the setup at this price deserves careful consideration rather than a reflexive chase.
#raised #analyst
6 hours ago
